Newswire (Published: Friday, September 6, 2019, Received: Friday, September 6, 2019, 5:01:50 PM CDT)
Word Count: 557
2019 SEP 06 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity Daily News -- Fresh data on Oncology - Prostate Cancer are presented in a new report. According to news reporting from Ancona, Italy, by NewsRx journalists, research stated, “: In human populations, a certain amount of data correlate obesity/body mass index (BMI) with urothelial cancer (UC) and prostate cancer (PCa) occurrence, however this is not fully elucidated at all stages of disease. In an attempt to shed light on uncertain areas in such field, in the present review we illustrate the main molecular mechanisms linking obesity and cancer, focusing on the correlation between obesity and tumor risk, disease progression and response to chemo-and immunotherapy in patients with UC and the predictive/prognostic role of obesity in PCa patients treated with the currently available therapeutic approaches.”
The news correspondents obtained a quote from the research from the Polytechnic University of the Marche Region, “We did a large-scale literature search on existing scientific websites focusing on keywords ‘obesity’, ‘body mass index (BMI)’, ‘urothelial cancer’, ‘prostate cancer’, ‘docetaxel’, ‘cabazitaxel’, ‘abiraterone acetate’, ‘enzalutamide’, and ‘radium223’. Many adipocytes-induced molecules support tumor proliferation through activation of various cellular pathways. The available evidence in the postoperative setting do the role of BMI in oncological outcomes prediction still not completely clear. Likewise, in metastatic UC patients controversial results link the role of obesity/BMI with clinical outcomes of tumor response to chemotherapy. Adipose stromal cells recruitment, induced by PCa cells, from white adipose tissue to the tumor sites inducing cell invasiveness was associated with poor survival. Conflicting data, although more oriented towards a better survival outcome, resulted in obese patients treated with docetaxel. In PCa cell-lines a certain cabazitaxel chemo resistance adipose stromal cells (ASC)-mediated was demonstrated. In metastatic castration-resistant PCa patients with high BMI (>25 kg/m) receiving abiraterone acetate there were significant worse survival outcomes, while in enzalutamide patients BMI did not affect survival outcome. In radium 223 patients higher BMI significantly correlated with favorable overall survival. The main focus of this review was to understand the interplay between obesity/BMI and UC/PCa. Several pathogenic cellular pathways exploring the issue are discussed, opening the way to challenging tailored treatments on the basis of BMI.”
According to the news reporters, the research concluded: “Improving the knowledge of molecular connections between obesity and UC and PCa could favor the development of new therapies likely reducing chemo-and immunotherapy drug resistance.”
For more information on this research see: Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. Cancers, 2019;11(9):1225.
Our news journalists report that additional information may be obtained by contacting R. Montironi, Section of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, 60126 Ancona, Italy. Additional authors for this research include A. Cimadamore, F. Massari, F. Piva, G. Aurilio, A. Martignetti, M. Scarpelli, V. Di Nunno, L. Gatto, N. Battelli, L. Cheng, A. Lopez-Beltran and R. Montironi.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.3390/cancers11091225. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Treatments and Therapies